{
    "title": "110_s2618",
    "content": "The Act is titled the \"Paul D. Wellstone Muscular Dystrophy Community Assistance, Research, and Education Amendments Act of 2008\". It includes findings related to muscular dystrophy. The Act titled the \"Paul D. Wellstone Muscular Dystrophy Community Assistance, Research, and Education Amendments Act of 2008\" highlights the impact of muscular dystrophies on quality of life. Duchenne muscular dystrophy (DMD) is a common lethal genetic disorder affecting 1 in 3,500 boys annually, leading to progressive muscle weakness and death in late teens or twenties. Myotonic muscular dystrophy, the second most common form, affects 1 in 8,000 adults. Myotonic muscular dystrophy is a multisystemic disease that can affect people of any age, causing muscle atrophy, myotonia, and various complications in different body systems. It worsens with earlier onset and can be passed down through generations. Congenital myotonic muscular dystrophy is the most severe form, affecting infants and causing cognitive delays, with some cases leading to sudden death. Facioscapulohumeral muscular dystrophy (FSHD) is the second most prevalent adult muscular dystrophy, affecting 15,000 to 40,000 persons. It is genetically inherited with an estimated incidence of 1 in 20,000 persons. FSHD causes progressive muscle loss, weakness, reduced mobility, and can lead to hearing loss, vision problems, and respiratory issues. It may affect entire families and can result in severe physical disability. Congenital muscular dystrophies are a group of distinct diseases that begin at birth, varying in severity and affecting both muscle strength and brain function. These diseases can lead to premature infant death or severe physical disability. The unique epigenetic structure of FSHD, the second most prevalent adult muscular dystrophy, is unprecedented in other muscular dystrophies and genetic disorders, requiring novel approaches and research groups. Understanding this mechanism could benefit other areas of biomedical research, including cancer and other diseases of epigenetic origin. Muscular dystrophies, including various types like Becker, Duchenne, and limb-girdle, have a devastating impact on children and adults worldwide, leading to premature death or severe disability. These diseases impose physical and economic burdens on affected individuals. Progress has been made in the battle against muscular dystrophies due to the Muscular Dystrophy Community Assistance, Research and Education Amendments of 2001. Investments by the Federal Government include the creation of the MD Coordinating Committee and expansion of the National Institutes of Health. The National Institutes of Health has expanded its research portfolios and established Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers. Funding has been allocated for projects focused on DMD, including a $15,400,000 NIH U54 grant. The Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet) has been developed, along with a comprehensive education and outreach initiative. The NIH program in translational research for muscular dystrophy has grown significantly in recent years, funding large-scale projects to advance therapies for the disease. The National Institutes of Health awarded a $15,400,000 cooperative agreement to develop new small molecule drugs for the treatment of DMD and other forms of muscular dystrophy. This project involves a unique research collaboration between private, public, and nonprofit partners to identify new treatments for muscular dystrophy. Additionally, 3 other major cooperative agreements have been awarded for therapy development projects in the muscular dystrophies. Advancements in muscular dystrophy research, funded by the MD-CARE Act, have led to collaborations between national nonprofit organizations, academic institutions, and industry. These collaborations have resulted in the development of potential therapies for various types of muscular dystrophies, improving patient care and quality of life. Recent advancements in muscular dystrophy research, funded by the MD-CARE Act, have led to the development of potential therapies for various types of muscular dystrophies. However, there is still a shortage of qualified researchers in the field, and many healthcare professionals lack the knowledge to detect and diagnose the disease early, leading to delays in symptom management. Education and outreach are urgently needed to address these gaps. Communities urgently need education and outreach for competent engagement in genetic testing and counseling, as well as patient characterization for research and clinical trials. Support for clinical research infrastructure is crucial to bring new therapeutic targets for muscular dystrophies to human trials. Improved communications and partnerships are essential for developing effective treatments for individuals with muscular dystrophy. Renewed effort is needed to improve communications and partnerships between patients, advocacy groups, researchers, and clinical care providers. Continued focus and investment are required to translate federally funded research into therapeutic targets quickly. SEC. 3. EXPANSION, INTENSIFICATION, AND COORDINATION OF ACTIVITIES OF NATIONAL INSTITUTES OF HEALTH WITH RESPECT TO RESEARCH ON MUSCULAR DYSTROPHY. Section 404E of the Public Health Service Act is amended to establish the 'Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers' and prioritize enhancing clinical research infrastructure for testing therapies for muscular dystrophy. Authorization of appropriations is provided for carrying out this section. Authorization of appropriations is provided for carrying out this section for fiscal years 2008 through 2012. Development and expansion of activities of Centers for Disease Control and Prevention regarding epidemiological research on muscular dystrophy. Section 317Q of the Public Health Service Act is amended to include provisions for data collection on patients in the Muscular Dystrophy Surveillance, Tracking and Research Network. The Secretary must ensure that patient data is regularly updated to reflect changes in condition over time, especially improvements due to adherence to care or treatment. Annual reporting requirements are also specified. The Community Assistance, Research, and Education Amendments Act of 2008 require the Director of the CDC to submit annual reports on activities, data, and findings from MD STARnet sites funded under the act. The reports also outline data collection objectives and strategies every 2 years. The CDC is required to release health outcome data for people with muscular dystrophy. The Muscular Dystrophy Community Assistance, Research, and Education Amendments of 2001 have been amended to include requirements for the Centers for Disease Control and Prevention to partner with the muscular dystrophy patient community and disseminate Duchenne-Becker Muscular Dystrophy care considerations. Additionally, standards of care are addressed in the following section. SEC. 6. STANDARDS OF CARE. The Director shall evaluate scientific evidence for Duchenne-Becker Muscular Dystrophy care considerations and replicate the methodology for other muscular dystrophies."
}